Introduction
Increasing prevalence of multidrug resistant (MDR) bacteria and limited treatment options have necessitated the discovery of new antibacterial and resistance modifying agents. Resistance modifying agents (RMAs) are compounds which potentiate the activity of an antibiotic against a resistant strain and may also target and inhibit MDR mechanisms [1] . An application of a RMA with a conventional antibiotic is well accepted. Augmentin ® is an important example which uses a combination of amoxicillin and a microbial-derived beta-lactamase inhibitor as a RMA (clavulanate) [2] . Recent experiments have additionally demonstrated that molecules capable of blocking the action of efflux pumps have the potential to circumvent antimicrobial resistance [3] . Stermitz et al reported for the first time the synergistic effect of a plant-derived ineffective antibacterial agent, berberine and a multidrug resistance pump inhibitor, 5′-methoxyhydnocarpin produced by Berberis species against S. aureus [4] . Furthermore, several plant-derived alkaloids and polyphenols such as reserpine, quinine, harmaline, piperine, epigallocatechin gallate, tellimagrandin I, and rugosin B have been demonstrated to act as efflux pump inhibitors for Gram positive pathogen [5] . Recently, we have demonstrated that Holarrhena antidysenterica (Linn) Wall. (Apocynaceae) possessed a Objective: To investigate the efficacy of 17 ethnomedicinal plants belonging to Apocynaceae family used in combination with 16 conventional antibiotics against non-multidrug resistant-, multidrug resistant (MDR)-, and extensive drug resistant (XDR) Acinetobacter baumannii (A. baumannii). Methods: Antibacterial activity and resistance modifying ability of 272 combinations were determined by growth inhibition assays and further confirmed by time-kill assay. Results: Among the combinations of the antibiotics with Apocynaceae ethanol extracts on this pathogen, 15 (5%) had synergistic effects, 23 (8%) had partial synergistic effects and 234 (86%) had no effects. Synergistic activity was observed mostly when the Apocynaceae extracts were combined with rifampicin or cefazolin. Interestingly, 10 out of 17 combinations between the extracts and rifampicin displayed synergistic or partial synergistic behaviors. Holarrhena antidysenterica extract was additionally tested to restore rifampicin activity against clinical isolates of MDR and XDR A. baumannii. With respect to total or partial synergy, 70% was XDR A. baumannii isolates and 66% was MDR A. baumannii isolates. Conclusions: Holarrhena antidysenterica extract clearly demonstrated the ability to restore rifampicin activity against both A. baumannii ATCC19606 and clinically isolated A. baumannii. Additional studies examining its active principles as well as mechanisms of actions such as the effects on efflux pumps and outer membrane permeability alterations are recommended. remarkable RMA ability in combination with novobiocin against Acinetobacter baumannii (A. baumannii) ATCC 19606 [6] .
To our knowledge, there is no report on the RMA activity of other ethnomedicinal plants from the family Apocynaceae as well as relatively few studies have been carried out to evaluate RMA activities of plant-derived compounds on A. baumannii. Therefore, this study was aimed to investigate the RMA activity of medicinal plants belonging to the family Apocynaceae in combination with conventional antibiotics against A. baumannii ATCC 19606 and a collection of clinical A. baumannii isolates.
Materials and methods

Bacterial strains and culture condition
Clinically isolated A. baumannii isolates were obtained from Songklanakarin Hospital from pus (n=1), blood (n=2), sputum (n=5), body fluid (n=4), and urine (n=7) samples of infected patients. A. baumannii ATCC 19606 was employed in this study as a quality control strain. The strains were cultured on tryptic soy agar (TSA) (Difco Laboratories, Detroit, MI) and incubated at 37 曟 overnight. Colonies from the plates were grown in Mueller Hinton broth (MHB) (Difco Laboratories, Detroit, MI) at 37 曟 for [18] [19] [20] [21] [22] [23] [24] h and adjusted to McFarland standards No. 0.5. The suspensions were further diluted with MHB to obtain inocula containing 1伊10 6 CFU/mL. Susceptibility test was performed by the disk diffusion method according to Clinical and Laboratory Standard Institute (CLSI) recommendations [7] . MDR phenotypes were defined as isolates resistant to at least three different antimicrobial classes and the isolates resistant to all tested agents were classified as extensive drug resistant (XDR) phenotypes [8] .
Medicinal plant materials and extraction
Seventeen selected plant species belonging to the Apocynaceae family were selected based on their potential use in folk medicine for treatments of diseases, or known to have antimicrobial activities as described in Table 1 . The medicinal plants were purchased from medicinal herb retailers in Songkhla, Thailand and authenticated by a taxonomist, Dr. Katesarin Maneenoon and voucher specimens were deposited at the Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. The samples were washed with distilled water and dried at 60 曟 overnight. Ground plant material (100 g) was macerated with 95% (v/v) ethanol (500 mL) for 7 days at room temperature. After filtrations through a Whatman No. 1 paper, the filtrates were concentrated using a rotatory evaporator, and kept at 55 曟 until they were completely dried. Yields (%; w/w) of each extracts were calculated as the ratio of the weight of the extract to the weight of the herb powder. A stock solution (200 mg/mL) was prepared by dissolving the dried extract in dimethylsulfoxide (DMSO) (Merck, Germany).
Resistant modifying ability of medicinal plant extracts
Intrinsic anti-A. baumannii ATCC19606 activities of the Apocynaceae extracts and a panel of selected antibiotics consisting of cell wall inhibitors (penicillin, oxacillin, ampicillin, imipenem, cefazolin, ceftazidime, and vancomycin), protein synthesis inhibitors (amikacin, gentamicin, streptomycin, fusidic acid, erythromycin, and tetracycline), DNA synthesis inhibitors (novobiocin and ciprofloxacin), and RNA synthesis inhibitors (rifampicin) were determined by growth inhibition assays as previously described [9] . Briefly, the culture, containing 1伊10 6 CFU/mL (100 毺 L) was inoculated into a 96-well microtiter plate containing 50 毺 L of the extract (1 000 毺 g/mL) or the antibiotic and 50 毺 L of MHB. The antibiotics were purchased from Becton Dickinson Microbiology Systems (Sparks, MD, USA), Difco (Detroit, MI, USA) or made using the laboratory collection of antibiotics. The intrinsic antibacterial activity was exhibited as the percentage of growth inhibition (GI) after incubation at 37 曟 for 18 h and calculated from the following equation: GI (%) = (OD control -OD test )/OD control ×100. (1) where, OD control is optical density (OD) 620 nm of bacteria culture in MHB supplemented with 1% (v/v) DMSO as a positive control and OD test is OD 620 nm of the bacterial culture in MHB supplemented with the tested agent. The OD test of respective blanks having only the extract was subtracted to give the final OD test . GI A and GI E represent the percentage inhibition of bacterial growth of the antibiotic and extract, respectively.
Resistance modifying ability of each extract was observed by adding of 50 毺 L of the tested extract into the tested plate supplemented with the antibiotic instead of MHB. This biological activity was exhibited as the percentage of growth inhibition as well but calculated from the following equation: %Growth inhibition of the combination (GI C ) = OD control -OD test )/OD control ×100. (2) where, OD control is OD 620 nm of the positive control culture and OD test is OD 620 nm of the bacterial culture in MHB supplemented with the extract in combination with the antibiotic.
The interpretation of the combination was classified as synergism when GI C /GI A and GI C /GI E ratios were ≥2.0, partial synergism when 1.5≤the ratios<2.0, and no effect when the ratios <1.5. Ellagic acid at 40 毺 mol/L was included as a positive control RMA in combination with erythromycin, novobiocin, and rifampicin against A. baumannii ATCC19606.
The efficacy of combination therapy of the promising medicinal plants in combination with the antibiotics was additionally determined against 19 clinically isolated A. baumannii isolates using the growth inhibition assay as described above and further confirmed by a time-kill assay.
Results
In this present investigation, the growth inhibition assay was employed to develop another approach for combating A. baumannii infections using medicinal plants to potentiate the activity of antibiotics. Independently, 15 out of 17 tested ethanol extracts at concentration of 1 000 毺 g/mL displayed low inherent anti-A. baumannii activity (% of bacterial growth inhibition was less than 75%) ( Table 2 ). Only Alstonia macrophylla and Carissa spinarum which completely inhibited the bacterial growth at this concentration possessed moderate antibacterial activity.
From 272 combinations tested between 17 medicinal plants and 16 antibiotics, 15 (5%) showed synergism, 23 (8%) had partial synergistic interaction, and 234 (86%) had no effect. Synergistic activity was observed mostly when the Apocynaceae extracts were combined with rifampicin or cefazolin against A. baumannii ATCC19606. Synergistic behaviors were displayed in cefazolin in combination with Alstonia scholaris, Cerbera odollam, Holarrhena antidysenterica, Nerium oleander, or Thevetia peruviana or rifampicin in combination with Adenium obesum, Holarrhena antidysenterica, Plumeria obtuse, Thevetia peruviana, or Wrightia pubescens (Table 3) .
The ability of a representative effective resistance modifier, Holarrhena antidysenterica to potentiate the antibacterial activity of rifampicin against clinically isolated A. baumannii was additionally evaluated to explore the potential of developing a promising RMA (Table 4 ). The interaction between the ethanol extract and rifampicin was synergistic and partially synergistic in 8 (42.1%) and 3 (15.8%) isolates of A. baumannii tested, respectively. With respect to total or partial synergy, 70%, 66%, and 33% of the isolates were XDR A. baumannii, MDR A. baumannii, and non-MRD A. baumannii, respectively.
The synergistic effect of this combination was further confirmed by time-kill assay as illustrated in Figure  1 . At the tested concentration, the extract exhibited no antibacterial potencies, but it was shown to be a powerful RMA in combination with rifampicin against A. baumannii ATCC 19606, non-MDR A. baumannii, and XDR A. baumannii. An antibacterial activity of phytochemicals is considered to be significant if MIC values are below 100 毺 g/mL for crude extract and 10 毺 g/mL for pure compounds [37] . b The percentage inhibition of bacterial growth was calculated by using the equation:
Bacterial growth inhibition (%) = (OD control -OD test ) /OD control ×100. Where, OD control represents the optical density at 620 nm of the control culture in MHB containing 1% (v/v) DMSO, OD test represents the optical density at 620 nm of the culture in MHB containing 1 mg/mL of the ethanol extract. The OD test of respective blanks having only the extract was subtracted to give the final OD test .
Discussion
Uses of rifampicin in combination with colistin have been studied for the treatment of MDR A. baumannii infections. Both in vitro studies and clinical studies were employed to recommend the safety and clinical effectiveness of rifampicin in combination with colistin against this pathogen [10] [11] [12] [13] . It was suggested that colistin probably causes rapid permeabilization of the outer membrane, which enhances penetration and activity of rifampicin. Similarly, plant-derived compounds that act as permeabilizers such as coriander oil (Coriandrum sativum) [14] , geraniol (Helichrysum italicum) [15] , and [6]-dehydrogingerdione and [10]-gingerol (Zingiber officinale) [16] have been shown to reduce the resistance of A. baumannii to other antibiotics. Even though antibacterial activity of Holarrhena antidysenterica and its constituents have been reported, there is to our knowledge no published scientific literature of RMA activity on rifampicin of this plant or its constituents.
Rifampicin resistance in A. baumannii is related to the synergistic interaction between modifications of antibiotic permeability, enzymatic modification by rifampicin ADP-ribosyl-transferase (arr-2), or mutation in rpoB [17] [18] [19] . A recent finding by Giannouli et al proposed that the combined treatment with colistin/rifampicin versus colistin alone were evident only in A. baumannii strains with no chromosomal mutations in RNA polymerase 毬 -subunit rpoB target gene [11] . Interestingly, phenylalanine arginine 毬 -naphthylamide (PA 毬 N), an efflux pump inhibitor, reduced the minimun inhibitory concentration of rifampicin at 256 毺 g/mL by approximately 30-fold in A. baumannii isolate that showed no mutation in the rpoB target gene [11] .
The present results indicate that the ethanol extract of Holarrhena antidysenterica is a promising resistance modifying agent for rifampicin against A. baumannii, due to its synergistic effect in combination with rifampicin against both A. baumannii ATCC19606 and clinically isolated A. baumannii. The findings may lead to development of an effective alternative treatment in combating the antimicrobial resistance in A. baumannii. Therefore, the mechanisms of action of this combination as well as the active constituents of Holarrhena antidysenterica should be further investigated.
